上海地区孕妇重要疫苗可预防传染病抗体水平研究

注册号:

Registration number:

ChiCTR2500103811 

最近更新日期:

Date of Last Refreshed on:

2025-06-05 16:44:22 

注册时间:

Date of Registration:

2025-06-05 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

上海地区孕妇重要疫苗可预防传染病抗体水平研究

Public title:

A Study on Antibody Levels against Important Vaccine-Preventable Infectious Diseases among Pregnant Women in Shanghai

注册题目简写:

English Acronym:

研究课题的正式科学名称:

上海地区孕妇重要疫苗可预防传染病抗体水平研究

Scientific title:

A Study on Antibody Levels against Important Vaccine-Preventable Infectious Diseases among Pregnant Women in Shanghai

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

顾蔚蓉 

研究负责人:

顾蔚蓉 

Applicant:

Weirong Gu 

Study leader:

Weirong Gu 

申请注册联系人电话:

Applicant telephone:

+86 21 3318 9900

研究负责人电话:

Study leader's
telephone:

+86 21 3318 9900

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

guweirong@fudan.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

guweirong@fudan.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市黄浦区方斜路419号

研究负责人通讯地址:

上海市黄浦区方斜路419号

Applicant address:

419 Fangxie Road, Huangpu District, Shanghai

Study leader's address:

419 Fangxie Road, Huangpu District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

复旦大学附属妇产科医院

Applicant's institution:

Obstetrics and Gynecology Hospital of Fudan University

研究负责人所在单位:

复旦大学附属妇产科医院

Affiliation of the Leader:

Obstetrics and Gynecology Hospital of Fudan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

妇产科伦审 2023-120

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

复旦大学附属妇产科医院伦理委员会

Name of the ethic committee:

The Ethics Committee of Obstetrics and Gynecology Hospital of Fudan University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-10-09 00:00:00

伦理委员会联系人:

鞠丹丹

Contact Name of the ethic committee:

Dandan Ju

伦理委员会联系地址:

上海市黄浦区方斜路419号

Contact Address of the ethic committee:

419 Fangxie Road, Huangpu District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 3318 9900

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学附属妇产科医院

Primary sponsor:

Obstetrics and Gynecology Hospital of Fudan University

研究实施负责(组长)单位地址:

上海市黄浦区方斜路419号

Primary sponsor's address:

419 Fangxie Road, Huangpu District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属儿科医院

具体地址:

上海市闵行区万源路399号

Institution
hospital:

Children's Hospital of Fudan University

Address:

399 Wanyuan Road, Minhang District, Shanghai

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属妇产科医院

具体地址:

上海市黄浦区方斜路419号

Institution
hospital:

Obstetrics and Gynecology Hospital of Fudan University

Address:

419 Fangxie Road, Huangpu District, Shanghai

经费或物资来源:

科室发展基金

Source(s) of funding:

Section Development Fund

研究疾病:

百日咳  

Target disease:

pertussis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

研究本地区孕妇疫苗接种现况、相关病原保护性抗体水平及其影响因素,从而为政府相关部门提供特殊人群疫苗接种方案的相关信息,为上海地区育龄女性和孕妇疫苗接种策略和婴儿疫苗接种程序优化提供依据,减少高危人群特别是新生儿及婴幼儿的水痘、百日咳、麻疹、呼吸道合胞病毒等疾病发生率。  

Objectives of Study:

To study the current status of vaccination for pregnant women, the level of protective antibodies against relevant pathogens and their influencing factors in the region, so as to provide relevant government departments with information on vaccination programs for special populations, to provide a basis for the optimization of vaccination strategies for women of childbearing age and pregnant women as well as infant vaccination programs in Shanghai, and to reduce the incidence of diseases such as chickenpox, whooping cough, measles, respiratory syncytial virus, etc., in the at-risk population, especially in newborns, infants and toddlers. The incidence of the disease will be minimized.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

建卡信息或分娩信息严重缺失,失访或个人因素转院,知晓且不同意参加本研究。

Exclusion criteria:

Significantly missing card information or delivery information, lost to visit or transferred for personal factors, aware of and did not agree to participate in this study.

研究实施时间:

Study execute time:

From 2024-04-23 00:00:00 To 2025-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-04-23 00:00:00 To 2025-01-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

600

Group:

Trial Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属妇产科医院 

单位级别:

三甲 

Institution
hospital:

Obstetrics and Gynecology Hospital of Fudan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属儿科医院 

单位级别:

三甲 

Institution
hospital:

Children's Hospital of Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

水痘IgG抗体

指标类型:

主要指标

Outcome:

Varicella IgG Antibody

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

百日咳IgG抗体

指标类型:

主要指标

Outcome:

Pertussis IgG antibody

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻疹IgG抗体

指标类型:

主要指标

Outcome:

Measles IgG antibody

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呼吸道合胞病毒IgG抗体

指标类型:

主要指标

Outcome:

Respiratory syncytial virus IgG antibody

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新型冠状病毒肺炎IgG抗体

指标类型:

主要指标

Outcome:

Novel Coronavirus Pneumonia IgG Antibody

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血清

组织:

Sample Name:

serum sample

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 50 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

否。

Randomization Procedure (please state who generates the random number sequence and by what method):

None.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

因部分根据病史队列数据为基础的科学论文等未完全公开、发表,故定协议共享,保护期限5年。拟将数据在国家人口健康科学数据中心(http://www.ncmi.cn/)进行存档。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Due to the fact that some scientific papers and other materials based on historical disease cohort data have not been fully disclosed or published, the data will be shared under an agreement with a protection period of 5 years. It is planned to archive the data at the National Population Health Science Data Center (http://www.ncmi.cn/).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-06-05 16:44:01